Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00504816 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00504816 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 22 participants.
The verdict
NCT00504816, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this research study is to demonstrate a lack of effect of multiple doses of GSK189075 on the PK of an oral contraceptive pill in healthy female subjects. To estimate the effects of GSK189075 on hormonal levels and on birth control.
Interventions
- DRUG GSK189075
- DRUG Brevicon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00504816
The ClinicalTrials.gov registry entry for NCT00504816 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GSK189075 is the first listed.
NCT00504816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00504816 about?
NCT00504816 is a clinical study titled "A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers". The purpose of this research study is to demonstrate a lack of effect of multiple doses of GSK189075 on the PK of an oral contraceptive pill in healthy female subjects. To estimate the effects of GSK189075 on hormonal levels and on birth control.
What is the current status of trial NCT00504816?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2007-04. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00504816?
The interventions under investigation include: GSK189075 (DRUG), Brevicon (DRUG).
Who is sponsoring clinical trial NCT00504816?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.